-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, DgBzCg1+rJjcFjWaQjTCwM/jLYQoowwK9crPksoAqLqxJUbcwkTMR94PE6J3v+6R bS0i8+R7y6eLtLb3EKzNcw== 0001209191-10-023461.txt : 20100423 0001209191-10-023461.hdr.sgml : 20100423 20100423141910 ACCESSION NUMBER: 0001209191-10-023461 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20100421 FILED AS OF DATE: 20100423 DATE AS OF CHANGE: 20100423 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: COOK JOSEPH C JR CENTRAL INDEX KEY: 0001024003 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-50679 FILM NUMBER: 10766876 MAIL ADDRESS: STREET 1: 9360 TOWNE CENTRE DR CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CORCEPT THERAPEUTICS INC CENTRAL INDEX KEY: 0001088856 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 770487658 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 149 COMMONWEALTH DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 BUSINESS PHONE: 650.688.8803 MAIL ADDRESS: STREET 1: 149 COMMONWEALTH DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 4 1 doc4.xml FORM 4 SUBMISSION X0303 4 2010-04-21 0 0001088856 CORCEPT THERAPEUTICS INC CORT 0001024003 COOK JOSEPH C JR C/O CORCEPT THERAPEUTICS INCORPORATED 149 COMMONWEALTH DRIVE MENLO PARK CA 94025 1 0 0 0 Common Stock 304600 D Common Stock 1130000 I By Farview Mgmt Co. Common Stock 2010-04-21 4 P 0 73427 1.66 A 777411 D Common Stock 2010-04-21 4 P 0 61190 1.66 A 476016 D Stock option (right to buy) 7.00 2012-04-17 Common Stock 50000 50000 D Stock Option (right to buy) 7.00 2013-11-23 Common Stock 25000 25000 D Stock option (right to buy) 2.70 2017-12-19 Common Stock 15000 15000 D Warrants 2.77 2008-03-25 2015-03-24 Common Stock 31570 119831 D Stock Option (right to buy) 2.23 2018-06-10 Common Stock 15000 15000 D Warrants 2.77 2008-03-25 2015-03-24 Common Stock 14402 14402 I By Farview Mgmt Co. Warrants 2.77 2008-03-25 2015-03-24 Common Stock 25649 25649 D Stock option (right to buy) 0.96 2019-06-11 Common Stock 30000 30000 D Warrants 1.66 2009-10-16 4 X 0 73427 0.125 D 2009-10-16 2012-10-16 Common Stock 73427 0 D Warrants 1.66 2009-10-16 4 X 0 61190 0.125 D 2009-10-16 2012-10-16 Common Stock 61190 0 D Warrants 2.96 2010-04-21 4 P 0 73427 0.125 A 2010-04-21 2013-04-21 Common Stock 73427 73427 D Warrants 2.96 2010-04-21 4 P 0 61190 0.125 A 2010-04-21 2013-04-21 Common Stock 61190 61190 D These securities are held by Farview Management Co., LLP, of which the reporting person is a general partner. Issuance of common stock upon exercise of warrants in accordance with the Securities Purchase Agreement dated as of October 12, 2009. Does not include 350,000 shares of which Mr. Cook disclaims any beneficial ownership interest. Immediately exercisable subject to a right of repurchase by Corcept Therapeutics Incorporated that shall lapse at the rate of 20% of the total option shares on 4/17/2003 and an additional 1.67% of the total option shares on each monthly anniverary of 4/17/2003 thereafter. Immediately exercisable subject to a right of repurchase by Corcept Therapeutics Incorporated that shall lapse at the rate of 20% of the total option shares on 11/23/2004 and an additional 1.67% of the total option shares on each monthly anniverary of 11/23/2004 thereafter. Exercisable with respect to 8.3334% of the total option shares on each monthly anniversary of June 11, 2007 so that the entirety of the option grant will vest within one year. Does not include 13,995 warrants of which Mr. Cook disclaims any beneficial ownership interest. Exercisable with respect to 8.3334% of the total option shares on each monthly anniversary of June 10, 2008 so that the entirety of the option grant will vest within one year. Exercisable with respect to 8.3334% of the total option shares on each monthly anniversary of June 11, 2009 so that the entirety of the option grant will vest on or before the date of Corcept's next Annual Meeting of Stockholders. Acquired from the issuer pursuant to a Warrant Purchase Agreement dated April 21, 2010 whereby purchase of the new warrants was conditioned upon the exercise of warrants that had been issued in October 2009 (see also Footnote #2 above). /s/ Joseph K. Belanoff, CEO of Corcept Therapeutics Incorporated attorney-in-fact 2010-04-23 -----END PRIVACY-ENHANCED MESSAGE-----